top of page

NCI-2023-04362

A Phase I, Open-label, Multicenter Study of ZL-1218 as a Single Agent and as Combination Therapy with Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Advanced Solid Tumor Malignancies


This medical study is designed to study the safety, tolerability, and pharmacokinetics of ZL-1218, a new drug that is being developed to treat advanced solid tumors. The drug will be given to patients in two ways: either as a single agent or in combination with an anti-PD-1 antibody. Anti-PD-1 antibodies are a type of immunotherapy that work by blocking a protein called PD-1, which helps cancer cells evade the immune system. By blocking PD-1, anti-PD-1 antibodies can help the immune system to attack and kill cancer cells.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

NCI-2023-04362

Clinical Trial Site: Sinai


To see all available clinical trials click here.



Recent Posts

See All

NCI-2022-06272

A first-in-human, phase 1/2, open-label, multi-center, dose-escalation and dose-expansion study to evaluate safety, tolerability,...

NCI-2019-04202

A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC. Some patients have a...

NCI-2022-05056

Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma (Phase II Study) This is a medical study to evaluate...

Comments


bottom of page